Patent litigation trends: the future of biologics?

20 minute read
06 December 2021

Biologics and biosimilars innovation and production is on the rise. But how is this affecting intellectual property (IP) trends and patent litigation?

As the biologics market continues to expand, patent litigation is also increasing. Our report 'Patent litigation trends: the future of biologics and next generation therapies' examines what we're likely to see in the next few years in this industry and how litigators can prepare for the increase of innovation in biosimilars and next generation therapies.

Our Life Sciences team and global IP lawyers teamed up with Life Sciences IP Review to survey those at the forefront of the biologics and next generation therapies industry to better understand the emerging trends in IP law. The findings share companies' own experiences with these complex molecules, the issues they present and the pattern of litigation arising.

In this report, we compare our own perceptions of the industry with those of companies at the forefront of these developments. Our findings focus on what litigators currently do when faced with patent claims in cases involving biosimilars and biologics, as well as what trends they expect to see in future patent disputes.

Through exploring the current situation and individual predictions for the future, our study gives you valuable insight into the following:

  • Biologics vs biosimilars - headline trends in approaches to biosimilar litigation
  • Key challenges that may occur in patent litigation for biologics and biosimilars
  • Different types of patent litigation and alternative strategies
  • Skinny labelling and carve out
  • The current patents system and the possible evolution of biologics regulation
  • The key jurisdictions leading the way in biosimilars patent litigation
  • The launch of the Unified Patent Court in Europe and its possible effect on future cases

To find out more about patent litigation for biologics and next generation therapies, enter your details below to download our report.

Our Life Sciences team

Whether small molecules, biologics, medical devices or a whole range of other patent types, our Life Sciences team has the technical expertise to guide you through the unique challenges you face throughout your life cycle. Our life sciences and IP lawyers are highly commended in The Legal 500 as the 'go-to names for patent licensing' as well as recognition for their work with world-leading companies in patent infringement cases.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.